Status:
COMPLETED
Safety of H1N1 Influenza Vaccination in Pregnant Women
Lead Sponsor:
Jiangsu Province Centers for Disease Control and Prevention
Conditions:
Virus Diseases
Respiratory Tract Infections
Eligibility:
FEMALE
18-35 years
Phase:
PHASE4
Brief Summary
Since October 2009, H1N1 influenza vaccine has developed and approved of immunization in population in China. However, there was little epidemiological evidence of safety when vaccinated in healthy pr...
Eligibility Criteria
Inclusion
- Healthy pregnant women
- Be able to show legal identity card for the sake of recruitment
- Be able to understand and sign the informed consent
Exclusion
- Cases, cured cases and close contact of influenza A (H1N1) virus
- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Autoimmune disease or immunodeficiency
- Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- Diabetes mellitus (type I or II), with the exception of gestational diabetes
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing
- Administration of any other investigational research agents within 30 days before the dosing
- Administration of any live attenuated vaccine within 30 days before the dosing
- Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- Axillary temperature \> 37.0 centigrade at the time of dosing
- Psychiatric condition that precludes compliance with the protocol
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT01842997
Start Date
October 1 2009
End Date
December 1 2010
Last Update
April 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangshui Center for Disease Control and Prevention
Xiangshui, Jiangsu, China, 224600